Detection and Analysis of MBC With Heterogeneous ER Expression
To investigate the treatment pattern and efficacy of MBC patients with ER heterogeneity using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
Breast Cancer
PFS, Progression free survival, 6 weeks
Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0, 6 weeks
To investigate the treatment pattern and efficacy of MBC patients with ER heterogeneity using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).